- Edesa Biotech appoints a new CFO, influencing stock activity.
- Analysts predict significant potential upside for EDSA shares.
- Current brokerage recommendations suggest an "Outperform" status.
Edesa Biotech (EDSA) has announced a key leadership change that has captured investor attention. Peter J. Weiler is set to take over as the new Chief Financial Officer, effective May 1, 2025. This transition follows the tenure of Stephen Lemieux, who will continue to serve as a financial advisor. In response to this announcement, EDSA shares experienced a notable 4.8% decline in post-market trading on Friday.
Wall Street Analysts Forecast
Investors are eager for insights into Edesa Biotech's future, and Wall Street analysts provide a promising outlook. According to detailed forecasts from two analysts, the one-year average price target for Edesa Biotech Inc. (EDSA, Financial) is positioned at $19.00. Estimates vary, with a high of $21.00 and a low of $17.00. This average projection suggests a remarkable upside potential of 722.51% from the current trading price of $2.31. For further insights and detailed estimate data, visit the Edesa Biotech Inc. (EDSA) Forecast page.
The consensus among brokerage firms also adds an optimistic note for potential investors. Edesa Biotech Inc's (EDSA, Financial) average brokerage recommendation is currently rated at 2.0, which indicates an "Outperform" status. This rating is part of a scale ranging from 1 to 5, where 1 implies a Strong Buy and 5 suggests a Sell. Given this landscape, Edesa Biotech remains a company to watch closely for both current stakeholders and prospective investors.
